Recent Advances in Antiviral Drug Delivery Strategies

IF 4 4区医学 Q2 PHARMACOLOGY & PHARMACY AAPS PharmSciTech Pub Date : 2025-03-04 DOI:10.1208/s12249-025-03053-3

Dhwani Rana, Arvee Prajapati, Bharathi Karunakaran, Lalitkumar Vora, Derajram Benival, Anil B. Jindal, Rikin Patel, Vishvesh Joshi, Ashutosh Jamloki, Ujashkumar Shah

{"title":"Recent Advances in Antiviral Drug Delivery Strategies","authors":"Dhwani Rana, Arvee Prajapati, Bharathi Karunakaran, Lalitkumar Vora, Derajram Benival, Anil B. Jindal, Rikin Patel, Vishvesh Joshi, Ashutosh Jamloki, Ujashkumar Shah","doi":"10.1208/s12249-025-03053-3","DOIUrl":null,"url":null,"abstract":"<div><p>Viral infectious diseases have long posed significant challenges to public health, leading to substantial morbidity and mortality worldwide. Recent outbreaks, including those caused by coronaviruses, have highlighted the urgent need for more effective antiviral treatments. Existing therapies, while numerous, face limitations such as drug resistance, toxicity, poor bioavailability, and non-specific targeting, which hinder their effectiveness against new and emerging viruses. This review focuses on the latest advances in nanoplatform technologies designed to enhance drug solubility, provide sustained or targeted delivery, and improve the efficacy of antiviral therapies. Additionally, we explore how these technologies can be integrated with novel strategies like genetic modulation to combat viral infections more effectively. The review also discusses the potential of these innovations in addressing the challenges posed by current antiviral therapies and their implications for future clinical applications.</p><h3>Graphical Abstract</h3>\n<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":6925,"journal":{"name":"AAPS PharmSciTech","volume":"26 3","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AAPS PharmSciTech","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1208/s12249-025-03053-3","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Viral infectious diseases have long posed significant challenges to public health, leading to substantial morbidity and mortality worldwide. Recent outbreaks, including those caused by coronaviruses, have highlighted the urgent need for more effective antiviral treatments. Existing therapies, while numerous, face limitations such as drug resistance, toxicity, poor bioavailability, and non-specific targeting, which hinder their effectiveness against new and emerging viruses. This review focuses on the latest advances in nanoplatform technologies designed to enhance drug solubility, provide sustained or targeted delivery, and improve the efficacy of antiviral therapies. Additionally, we explore how these technologies can be integrated with novel strategies like genetic modulation to combat viral infections more effectively. The review also discusses the potential of these innovations in addressing the challenges posed by current antiviral therapies and their implications for future clinical applications.

Graphical Abstract

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

抗病毒给药策略的最新进展

病毒性传染病长期以来对公共卫生构成重大挑战，在世界范围内导致大量发病率和死亡率。最近的疫情，包括由冠状病毒引起的疫情，突出表明迫切需要更有效的抗病毒治疗。现有的治疗方法虽然众多，但面临诸如耐药性、毒性、生物利用度差和非特异性靶向等限制，这阻碍了它们对新出现的病毒的有效性。本文综述了纳米平台技术的最新进展，旨在提高药物的溶解度，提供持续或靶向递送，并提高抗病毒治疗的疗效。此外，我们还探讨了如何将这些技术与遗传调节等新策略相结合，以更有效地对抗病毒感染。这篇综述还讨论了这些创新在解决当前抗病毒疗法带来的挑战方面的潜力及其对未来临床应用的影响。图形抽象

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

AAPS PharmSciTech 医学-药学

CiteScore

6.80

自引率

3.00%

发文量

264

审稿时长

2.4 months

期刊介绍： AAPS PharmSciTech is a peer-reviewed, online-only journal committed to serving those pharmaceutical scientists and engineers interested in the research, development, and evaluation of pharmaceutical dosage forms and delivery systems, including drugs derived from biotechnology and the manufacturing science pertaining to the commercialization of such dosage forms. Because of its electronic nature, AAPS PharmSciTech aspires to utilize evolving electronic technology to enable faster and diverse mechanisms of information delivery to its readership. Submission of uninvited expert reviews and research articles are welcomed.